BR0012696A - Composição oftálmica - Google Patents

Composição oftálmica

Info

Publication number
BR0012696A
BR0012696A BR0012696-9A BR0012696A BR0012696A BR 0012696 A BR0012696 A BR 0012696A BR 0012696 A BR0012696 A BR 0012696A BR 0012696 A BR0012696 A BR 0012696A
Authority
BR
Brazil
Prior art keywords
ophthalmic composition
composition
ophthal
active agent
pharmaceutically active
Prior art date
Application number
BR0012696-9A
Other languages
English (en)
Inventor
Marcia Johanna Adam
Andrea Fetz
Gyorgy Lajos Kis
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Priority to BRPI0017528A priority Critical patent/BRPI0017528B8/pt
Publication of BR0012696A publication Critical patent/BR0012696A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Patente de Invenção: "COMPOSIçãO OFTáLMICA". A presente invenção refere-se a uma composição oftálmica contendo cetotifeno como um agente farmaceuticamente ativo.
BR0012696-9A 1999-07-23 2000-07-21 Composição oftálmica BR0012696A (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BRPI0017528A BRPI0017528B8 (pt) 1999-07-23 2000-07-21 uso de uma composição contendo sal de cetotifeno

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99114508 1999-07-23
PCT/EP2000/007030 WO2001007049A2 (en) 1999-07-23 2000-07-21 Ophthalmic composition comprising ketotifen

Publications (1)

Publication Number Publication Date
BR0012696A true BR0012696A (pt) 2002-04-09

Family

ID=8238654

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0017528A BRPI0017528B8 (pt) 1999-07-23 2000-07-21 uso de uma composição contendo sal de cetotifeno
BR0012696-9A BR0012696A (pt) 1999-07-23 2000-07-21 Composição oftálmica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0017528A BRPI0017528B8 (pt) 1999-07-23 2000-07-21 uso de uma composição contendo sal de cetotifeno

Country Status (20)

Country Link
US (2) US6777429B1 (pt)
EP (1) EP1198223A2 (pt)
JP (1) JP2003505419A (pt)
KR (1) KR20020012261A (pt)
CN (1) CN1358086A (pt)
BR (2) BRPI0017528B8 (pt)
CA (1) CA2377024A1 (pt)
CZ (1) CZ300614B6 (pt)
EE (1) EE05439B1 (pt)
HK (1) HK1046631A1 (pt)
HU (1) HU230738B1 (pt)
IL (1) IL146973A0 (pt)
MX (1) MXPA02000849A (pt)
NO (1) NO331228B1 (pt)
NZ (1) NZ516108A (pt)
PL (1) PL202496B1 (pt)
RU (1) RU2248789C2 (pt)
UA (1) UA74788C2 (pt)
WO (1) WO2001007049A2 (pt)
ZA (1) ZA200200425B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002345015A1 (en) * 2001-06-08 2002-12-23 Novartis Pharma Gmbh Ophthalmic once-a-day composition
AR034372A1 (es) * 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
AR034371A1 (es) * 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
WO2004064817A1 (ja) * 2003-01-22 2004-08-05 Nichiban Co., Ltd. 眼疾患治療用経皮吸収型製剤、その使用、及び眼疾患治療薬の眼の局所組織への移行方法
US20060089384A1 (en) * 2004-10-25 2006-04-27 Minno George E Ophthalmic compositions and methods of using the same
CA2585266C (en) * 2004-10-25 2010-10-19 Bausch & Lomb Incorporated Ophthalmic compositions and methods of using the same
US20070208058A1 (en) * 2004-10-25 2007-09-06 Bryant Roy W Stable Pharmaceutical Compositions and Methods of Making and Using Same
US20070048389A1 (en) * 2005-08-26 2007-03-01 Fu-Pao Tsao Stabilized and preserved ketotifen ophthalmic compositions
US20070077302A1 (en) * 2005-09-30 2007-04-05 Azaam Alli Methods for stabilizing ophthalmic compositions
CN101478949A (zh) 2006-06-16 2009-07-08 瑞泽恩制药公司 适合玻璃体内施用的vegf拮抗剂的制剂
US8445437B2 (en) * 2006-07-27 2013-05-21 The Brigham And Women's Hospital, Inc. Treatment and prevention of cardiovascular disease using mast cell stabilizers
AR059928A1 (es) 2006-09-29 2008-05-07 Johnson & Johnson Vision Care Metodos y dispositivos oftalmicos usados en el tratamiento de alergias oculares
WO2008153761A1 (en) * 2007-05-23 2008-12-18 Mastcell Pharmaceuticals, Inc. Methods
JP5460600B2 (ja) 2007-09-28 2014-04-02 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 肥満症治療における肥満細胞安定化薬
WO2009142772A2 (en) * 2008-05-23 2009-11-26 Mastcell Pharmaceuticals, Inc. Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
JP2012520880A (ja) * 2009-03-17 2012-09-10 アーシエックス セラピューティックス, インコーポレイテッド ケトチフェンの眼科用製剤および使用方法
RU2549472C1 (ru) * 2013-12-26 2015-04-27 Илья Александрович Марков Фармацевтическая композиция в форме капель для профилактики и лечения аллергических заболеваний глаз
CA3007276C (en) 2015-12-03 2021-12-28 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitor to treat macular degeneration in a patient population
CN111450051B (zh) * 2020-04-21 2022-03-18 武汉贝参药业股份有限公司 一种富马酸酮替芬口服溶液的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62277323A (ja) 1986-02-19 1987-12-02 Sankyo Co Ltd フマル酸ケトチフエン含有点眼液の製法
JPH07324034A (ja) * 1994-05-30 1995-12-12 Toa Yakuhin Kk フマル酸ケトチフェン含有の点眼剤
JPH11189533A (ja) * 1997-12-25 1999-07-13 Taisho Pharmaceut Co Ltd 点眼薬
EP0938896A1 (en) 1998-01-15 1999-09-01 Novartis AG Autoclavable pharmaceutical compositions containing a chelating agent

Also Published As

Publication number Publication date
US20020183359A1 (en) 2002-12-05
WO2001007049A3 (en) 2001-03-29
CN1358086A (zh) 2002-07-10
EE05439B1 (et) 2011-08-15
NO20020319L (no) 2002-01-21
NO20020319D0 (no) 2002-01-21
EE200200040A (et) 2003-04-15
EP1198223A2 (en) 2002-04-24
IL146973A0 (en) 2002-08-14
NO331228B1 (no) 2011-11-07
KR20020012261A (ko) 2002-02-15
CZ300614B6 (cs) 2009-07-01
HU230738B1 (hu) 2018-01-29
BRPI0017528B8 (pt) 2021-05-25
JP2003505419A (ja) 2003-02-12
HK1046631A1 (zh) 2003-01-24
PL202496B1 (pl) 2009-06-30
RU2248789C2 (ru) 2005-03-27
WO2001007049A2 (en) 2001-02-01
MXPA02000849A (es) 2002-07-30
NZ516108A (en) 2004-04-30
US6774137B2 (en) 2004-08-10
CA2377024A1 (en) 2001-02-01
ZA200200425B (en) 2002-10-30
PL352382A1 (en) 2003-08-25
BRPI0017528B1 (pt) 2017-06-13
CZ2002243A3 (cs) 2002-04-17
BRPI0017528A2 (pt) 2010-01-19
HUP0202243A2 (hu) 2002-12-28
HUP0202243A3 (en) 2006-03-28
UA74788C2 (en) 2006-02-15
US6777429B1 (en) 2004-08-17

Similar Documents

Publication Publication Date Title
BR0012696A (pt) Composição oftálmica
SE0001899D0 (sv) New compounds
DK1697370T3 (da) Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
BR0307893A (pt) Formulação oftálmica com sistema de goma
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
BR9917007A (pt) Moduladores de ccr5
BR0001468A (pt) ácidos dioxiciclopentil hidroxânicos
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
AU3850600A (en) Dalda analogs and their use
HUP0103781A2 (hu) Megismerési képesség javítására szolgáló gyógyszerkészítmények, melyek atipikus antipszihotikus szer és acetilkolinészteráz inhibitor kombinációját tartalmazzák
BR0210013A (pt) Gel oftálmico de pirenzepina
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
SE0102055D0 (sv) New Compounds
RS44204A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
BR9910024A (pt) Agente contra resfriado
NO20014240L (no) C16-umettede FP-selektive prostaglandinanaloger
DE60128100D1 (de) Analgetisches arzneimittel
PT1187611E (pt) Composicoes oftalmicas de histamina e sua utilizacoes
SE9802209D0 (sv) Novel compounds
BR9915123A (pt) Composição de uma substância farmaceuticamente ativa e dispensador
RS44304A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
BR0010699A (pt) Benzimidazóis substituìdos, sua produção e utilização dos mesmos como agente contra protozoários parasitários
EP1121932A4 (en) DRUGS FOR EYE DISEASES

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: A61K 31/445

Ipc: A61K 9/08 (2009.01), A61K 9/00 (2009.01), A61K 31/

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8 E 13 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.